IMbrave050: Phase 3 study of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

被引：0
|
作者：
Trojan, J. [1 ]
Chow, P. [2 ,3 ]
Chen, M. [4 ]
Cheng, A-L [5 ,6 ]
Kaseb, A. [7 ]
Kudo, M. [8 ]
Lee, H. C. [9 ]
Yopp, A. [10 ]
Zhou, J. [11 ]
Wang, L. [12 ]
Wen, X. [13 ]
Heo, J. [14 ,15 ]
Tak, W-Y [16 ]
Nakamura, S. [17 ]
Numata, K. [18 ]
Uguen, T. [19 ]
Hsieh, D. [10 ]
Cha, E. [20 ]
Hack, S. P. [20 ]
Lian, Q. [20 ]
Spahn, J. [20 ]
Wu, C. [21 ]
Qin, S. [22 ]
机构：
[1] Univ Klinikum Frankfurt, Frankfurt, Germany
[2] Natl Canc Ctr Singapore, Singapur, Singapore
[3] Duke NUS Med Sch, Singapur, Singapore
[4] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[5] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
[7] MD Anderson Canc Ctr, Houston, TX USA
[8] Kindai Univ, Osaka, Japan
[9] Univ Ulsan, Asan Med Ctr, Seoul, South Korea
[10] UT Southwestern Med Ctr, Dallas, TX USA
[11] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[12] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[13] 1st Hosp Jilin Univ, Jilin, Jilin, Peoples R China
[14] Pusan Natl Univ, Coll Med, Busan, South Korea
[15] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea
[16] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea
[17] Himeji Red Cross Hosp, Himeji, Hyogo, Japan
[18] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa, Japan
[19] Hosp Pontchaillou, Rennes, France
[20] Genentech Inc, San Francisco, CA USA
[21] Roche Holding Ltd, Shanghai, Peoples R China
[22] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P687
引用
收藏
页码：239 / 239
页数：1
相关论文
共 50 条
  • [21] IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDY
    Zhu, Andrew X.
    Finn, Richard
    Ducreux, Michel
    Hu, Youyou
    Sommer, Nicolas
    Verret, Wendy
    Kulik, Laura M.
    Galle, Peter R.
    HEPATOLOGY, 2021, 74 : 646A - 647A
  • [22] Adjuvant donafenib for patients with hepatocellular carcinoma at high risk of recurrence following radical resection: A multi-center, retrospective study in China
    Zhang, ShenYu
    Yang, Guibing
    Song, Ruipeng
    Wang, Wei
    Meng, Fanzheng
    Yin, Dalong
    Wang, Jiabei
    Zhang, Shugeng
    Cai, Wei
    Liu, Yao
    Wang, Jizhou
    Luo, Dayong
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 study
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Shao, Yu-Yun
    Finn, Richard S.
    Galle, Peter R.
    Ducreux, Michel
    Cheng, Ann-Lii
    Yamashita, Tatsuya
    Koga, Hironori
    Take, Ryosuke
    Yamada, Kyoko
    Asakawa, Takashi
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (04) : 401 - 412
  • [24] Effect of adjuvant lenvatinib (LEN) on tumour recurrence in patients with hepatocellular carcinoma (HCC) and high residual alpha-fetoprotein (AFP) following resection or ablation: A single-center, retrospective study
    Cai, L.
    Li, H.
    Guo, J.
    Zhao, W.
    Li, Y.
    Duan, Y.
    Hou, X.
    Cheng, L.
    Du, H.
    Shao, X.
    Diao, Z.
    Hao, Y.
    Li, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1308 - S1308
  • [25] ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection.
    Mao, Xianhai
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Zheng, Jinfang
    Fu, Changbo
    Xu, Guohui
    Bai, Yannan
    Wu, Changxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS632 - TPS632
  • [26] IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Lim, Ho Yeong
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li Daneng
    Verret, Wendy
    Shao Hui
    Liu Juan
    Li Lindong
    Zhu, Andrew X.
    Chen, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [27] CA209-9DX: phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
    Exposito, M. J. Jimenez
    Akce, M.
    Montero Alvarez, J. L.
    Assenat, E.
    Balart, L. A.
    Baron, A. D.
    Decaens, T.
    Heurgue-Berlot, A.
    Martin, A. O.
    Paik, S. W.
    Poulart, V.
    Sehbai, A. S.
    Takemura, N.
    Yoon, J-H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation
    Exposito, M. J. Jimenez
    Akce, M.
    Alvarez, J. L. M.
    Assenat, E.
    Balart, L. A.
    Baron, A. D.
    Decaens, T.
    Heurgue-Berlot, A.
    Martin, A. O.
    Paik, S. W.
    Poulart, V.
    Sehbai, A. S.
    Shimada, M.
    Takemura, N.
    Yoon, J-H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
    Pal, Sumanta Kumar
    Uzzo, Robert
    Karam, Jose Antonio
    Master, Viraj A.
    Donskov, Frede
    Suarez, Cristina
    Albiges, Laurence
    Rini, Brian
    Tomita, Yoshihiko
    Kann, Ariel Galapo
    Procopio, Giuseppe
    Massari, Francesco
    Zibelman, Matthew
    Antonyan, Igor
    Huseni, Mahrukh
    Basu, Debasmita
    Ci, Bo
    Leung, William
    Khan, Omara
    Dubey, Sarita
    Bex, Axel
    LANCET, 2022, 400 (10358): : 1103 - 1116
  • [30] Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial
    Khene, Zine-Eddine
    Borchiellini, Delphine
    Bensalah, Karim
    EUROPEAN UROLOGY, 2023, 83 (05) : 475 - 476
12345